The content on this site is intended for healthcare professionals only
Dr Judy Garber outlines some of the genes that have recently been connected with cancer prevalence, and explains the implications of these newly identified cancer sub-types.
Dr Garber also considers the potential benefits of gene sequencing but warns of the potentially prohibitive cost of personalised medicines.
Insights into germline genetic screening of breast cancer patients
New classification for identifying HR myeloma based on cytogenetic abnormalities
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems
Novel therapies and combinations in ovarian cancer
The current status of multiple myeloma diagnosis and treatment
